Equity
€104,589 ▲ 124%
Equity rose in 2025 from €46,743 to €104,589.
PharmSync
Lifetime
2 annual accounts with figures on one time axispeak €75,547 (2025)
€75,547▲ 30.9%
peak €57,846 (2025)
€57,846▲ 32.2%
peak €104,589 (2025)
€104,589▲ 124%
€32,100▲ 191%
Board1 name since 2023
1 directorKURDI Ammar
Documentsfilings and deeds
31-08-202631 days late
2025micro format
Gross margin from €57,723 to €75,547Result from €43,743 to €57,846Equity from €46,743 to €104,589Debts from €11,024 to €32,100Cash from €54,668 to €117,092
Key points
from the 2025 annual accountsTurnover
≈ €300,000 estimated
The micro format states no turnover.
Position in the sector
€57,846
Higher net result than 87% of companies in wholesale trade. Sector median €5,606 · 13,811 companies.
2025 accounts filed 31 days after the deadline
Checked score
92
Excellent
Financially stronger than 92% of micro companies in wholesale trade (NACE 46)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 26,891 companies (NACE 46, micro).
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
01-2025: 1.6%
02-2025: 1.7%▲ +0.1 percentage points vs 01-2025
03-2025: 1.7%● unchanged vs 02-2025
04-2025: 2.1%▲ +0.4 percentage points vs 03-2025
05-2025: 2.1%● unchanged vs 04-2025
06-2025: 2.4%▲ +0.3 percentage points vs 05-2025
07-2025: 2.6%▲ +0.2 percentage points vs 06-2025highest value
08-2025: 0.2%▼ -2.4 percentage points vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025lowest value
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.4%▲ +0.2 percentage points vs 07-2026
09-2026: 0.3%▼ -0.1 percentage points vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026
11-2026: 0.3%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Founded in 2023
Last filed accounts filed 31 days late; 1 of the last 3 accounts late
lowers risk
Liquidity: current ratio 4.25, cash €117,092
Equity €104,589 (76.5% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 90% of them on solvency, 90% on liquidity, 95% on profitability and 95% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 39,278 companies had the same profile as PharmSync has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of PharmSync itself is lower: 0.3% within 12 months. It rests on far more data about PharmSync than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for PharmSync. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €9,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity is ample, with a current ratio of 4.25 (5.2 in 2024), above the usual 1.5. Short-term debt is 23.5% and cash 85.7% of total assets. 23.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 31 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 2 filingsDeviation from the deadline
2025
31 days late
2024
2 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 2 accounts on average 15 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- KURDI Ammar 92 sharesdeed of 18-12-2023
- SADEK Rim 8 sharesdeed of 18-12-2023
Recent changes
Incorporation
Founding capital of €3,000, 100 shares · Founders: KURDI Ammar and SADEK Rim · Appointment: KURDI Ammar (director) · published on 18-12-2023 · Gazette deed
First establishment
Paviljoenlaan 10, Antwerp
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PharmSync Antwerp | €136,689 | €75,547 | 76.5% | - |
| Cedia Lier | €98,736 | €53,273 | 25.5% | - |
| EH Supply and Consulting Watermael-Boitsfort | €117,173 | €55,217 | 27.5% | - |
| Pharmacie Armée Britannique Forest | €158,501 | €116,864 | -8.2% | 1.5 |
| Mithridate Genk | €164,214 | €51,892 | -191.7% | - |
| Belgomed Hasselt | €184,456 | €59,645 | 40.2% | - |
| JANZ LAB Forest | €184,936 | €123,299 | 54.7% | - |
These companies have the same main activity as PharmSync: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €98,700 and €185,000, founded between 2022 and 2024.
Official details
Source: KBO- Status
- Active since 13-12-2023Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Establishment unit
- 2.353.816.0542610 Antwerp, since 13-12-2023
- Financial year end
- 31 December
- Peppol
- Reachable
Insights on PharmSync
PharmSync has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €104,589 and a net result of €57,846.
Its solvency ranks better than 80% of 13,805 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PharmSync
- What is the company number of PharmSync?
- The company number of PharmSync is 1003.300.890. The VAT number is the same number with BE in front: BE 1003.300.890.
- Where is PharmSync based?
- The registered office is at Paviljoenlaan 10, 2610 Antwerp.Company details
- What does PharmSync do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of PharmSync?
- PharmSync is a private limited company (BV).
- When was PharmSync founded?
- PharmSync was founded on 13-12-2023.
- Is PharmSync still active?
- Yes, PharmSync is an active enterprise in the KBO register.
- What is the turnover of PharmSync?
- The turnover in financial year 2025 is ≈ €300,000. This figure is estimated from the gross margin of €75,547 and 32 comparable companies (NACE 464). It probably lies between €160,000 and €410,000.Financials
- Is PharmSync profitable?
- In financial year 2025, PharmSync made a profit of €57,846.
- Where can I find the annual accounts of PharmSync?
- PharmSync filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PharmSync due?
- PharmSync must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.